<DOC>
	<DOCNO>NCT03006419</DOCNO>
	<brief_summary>Demonstrate low dose ( 3 mg/kg total ) rATG ( thymoglobulin ) similar efficacy ( delay graft function , slow graft function , biopsy proven acute rejection episode , infection , hospitalization , adverse event , graft loss death ) Basiliximab induction</brief_summary>
	<brief_title>Basiliximab vs Low-dose Thymoglobulin Induction Therapy Low Risk Kidney Transplant Patients</brief_title>
	<detailed_description>Introduction : The TAILOR study live donor kidney transplantation demonstrate 98 % one year patient graft survival 91 % 83 % 5 year rejection-free patient 93 % . The cumulative dose r ATG ( thymoglobulin ) 5.29 mg / kg 3 % adverse effect almost 50 % steroid free 12 month . Others explore benefit low dos r ATG ( thymoglobulin ) ( 3-5 mg / kg ) Basiliximab low-risk population demonstrate live donor recipient 8 year follow-up similar survival rate low BPAR rate rATG ( thymoglobulin ) ( p &lt; 0.05 ) good serum creatinine 3 5 year . The aim study demonstrate low dose ( 3 mg/kg total ) rATG ( thymoglobulin ) similar efficacy ( delay graft function , slow graft function , biopsy proven acute rejection episode , infection , hospitalization , adverse event , graft loss death ) Basiliximab induction . Material method : Prospective randomize study patient undergoing renal transplantation wish participate . 100 patient meet inclusion exclusion criterion time transplantation randomize Experimental reference therapy : Group A : Induction Basiliximab 20 mg IV day 0 day 4 Group B : rATG ( Thymoglobulin ) 1 mg / kg body weight per day day 0 , 1 2 total dose 3 mg / kg day . According protocol administration , condition delay administration ( WBC &lt; 2000 / mm3 / platelet &lt; 75,000 / mm3 ) ( 17 ) , administration may postpone day 7 posttransplant Posttransplant immunosuppression : Tacrolimus , mycophenolate mofetil steroid Outcome measure ( 12 month ) delay graft function slow graft function biopsy proven acute rejection episode infection hospitalization adverse event graft loss death</detailed_description>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female graft recipient older 18 year age . Informed consent participate study . First live donor kidney transplant recipient . Negative pregnancy test female participant Second kidney transplant . Multiple organ transplant recipient . ABO incompatibility positive crossover test prior transplantation . Antibody Reactive Panel ( PRA ) &gt; 30 % . Positive specific donor antibody ( DSA ) . Human immunodeficiency virus ( HIV ) positive patient . HBsAg HCV positive . Severe lung disorder . Severe allergy receive treatment prevent patient 's rRTAG administration . Leukocyte count 2000 / mm3 . Platelet count 75,000 / mm3 . History malignant disease organ system ( except skin basal cell carcinoma ) within last 5 year , regardless local recurrence metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>kidney transplantation</keyword>
	<keyword>induction</keyword>
	<keyword>thymoglobulin</keyword>
	<keyword>basiliximab</keyword>
	<keyword>acute rejection</keyword>
	<keyword>graft loss</keyword>
</DOC>